EcoDrugPlus

Atpase Na+/k+ Transporting Subunit Alpha 2

Ensembl ID : ENSPCOG00000028575
Gene Symbol: ATP1A2
4 Cross references
205 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Atpase Na+/k+ Transporting Subunit Alpha 3

Ensembl ID : ENSPCOG00000021213
Gene Symbol: ATP1A3
4 Cross references
134 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Atpase Na+/k+ Transporting Subunit Alpha 4

Ensembl ID : ENSPCOG00000015025
Gene Symbol: ATP1A4
4 Cross references
564 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Atpase Na+/k+ Transporting Subunit Beta 1

Ensembl ID : ENSPCOG00000017666
Gene Symbol: ATP1B1
4 Cross references
295 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Atpase Na+/k+ Transporting Subunit Beta 2

Ensembl ID : ENSPCOG00000028840
Gene Symbol: ATP1B2
4 Cross references
274 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Atpase Na+/k+ Transporting Subunit Beta 3

Ensembl ID : ENSPCOG00000021420
Gene Symbol: ATP1B3
4 Cross references
299 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Atr Serine/threonine Kinase

Ensembl ID : ENSPCOG00000019808
Gene Symbol: ATR
4 Cross references
206 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Axl Receptor Tyrosine Kinase

Ensembl ID : ENSPCOG00000023956
Gene Symbol: AXL
4 Cross references
197 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSPCOG00000024467
Gene Symbol: BRAF
4 Cross references
220 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Bcl2 Apoptosis Regulator

Ensembl ID : ENSPCOG00000022386
Gene Symbol: BCL2
4 Cross references
227 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Bcl2 Like 1

Ensembl ID : ENSPCOG00000022349
Gene Symbol: BCL2L1
4 Cross references
287 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Bcl2 Like 10

Ensembl ID : ENSPCOG00000015416
Gene Symbol: BCL2L10
4 Cross references
129 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).